ABSTRACT
INTRODUCTION: Patients with end-stage kidney disease (ESKD) represent a vulnerable group with multiple risk factors that are associated with poor outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite established susceptibility to infectious complications and the importance of humoral immunity in protection against SARS-CoV-2, few studies have investigated the humoral immune response to SARS-CoV-2 within this population. Here, we evaluate the seroprevalence of SARS-CoV-2 in patients awaiting renal transplantation and determine whether seroconverted patients with ESKD have durable and functional neutralizing activity against SARS-CoV-2. METHODS: Serum samples were obtained from 164 patients with ESKD by August 2020. Humoral immune responses were evaluated by SARS-CoV-2 spike S1 subunit and nucleoprotein semiquantitative enzyme-linked immunosorbent assay (ELISA) and SARS-CoV-2 spike pseudotype neutralization assay. RESULTS: All patients with ESKD with reverse-transcriptase polymerase chain reaction (RT-PCR)-confirmed infection (n = 17) except for 1 individual seroconverted against SARS-CoV-2. Overall seroprevalence (anti-S1 and/or anti-N IgG) was 36% and was higher in patients on hemodialysis (44.2%). A total of 35.6% of individuals who seroconverted were asymptomatic. Seroconversion in the absence of a neutralizing antibody (nAb) titer was observed in 12 patients, all of whom were asymptomatic. Repeat measurements at a median of 93 days from baseline sampling revealed that most individuals retained detectable responses although a significant drop in S1, N and nAb titers was observed. CONCLUSION: Patients with ESKD, including those who develop asymptomatic disease, routinely seroconvert and produce detectable nAb titers against SARS-CoV-2. Although IgG levels wane over time, the neutralizing antibodies remain detectable in most patients, suggesting some level of protection is likely maintained, particularly in those who originally develop stronger responses.
ABSTRACT
Pyrethroid resistant malaria vectors are widespread throughout sub-Saharan Africa and new insecticides with different modes of action are urgently needed. Pyriproxyfen is a juvenile hormone mimic that reduces fecundity and fertility of adult Anopheles mosquitoes when used as a contact insecticide. A long-lasting insecticidal net incorporating pyriproxyfen is under development. As wild, host-seeking females may succeed in blood-feeding at different intervals after initial contact with mosquito nets the aim of this study was to determine the effect that age and gonotrophic status (nulliparous or parous) and the interval between initial pyriproxyfen exposure and blood-feeding has in terms of subsequent reduced fecundity and fertility. Anopheles gambiae s.s. were exposed to pyriproxyfen LLIN for three minutes in WHO cone bioassays. Four regimens were tested with different blood-feeding intervals A-1 hour (nulliparous), B-1 hour (parous), C-24h (nulliparous), or D-120h (nulliparous) after pyriproxyfen exposure. Mosquito oviposition rate, fecundity and fertility of eggs were recorded for several days. All four treatment regimens produced levels of mortality similar to unexposed females. The overall reduction in reproductive rate of 99.9% for regimen A relative to the untreated net was primarily due to oviposition inhibition in exposed females (97%). Pyriproxyfen was equally effective against older parous mosquitoes and when blood-feeding was 24h after exposure. Regimen D produced a reduction in reproductive rate of 60.1% but this was of lesser magnitude than other regimens and was the only regimen that failed to reduce fertility of laid eggs, indicating the effects of pyriproxyfen exposure on reproduction are to some extent reversible as mosquitoes age. In an area of moderate to high mosquito net coverage a host-seeking mosquito is likely to contact a treated mosquito net before: (a) penetrating a holed net and blood-feeding shortly after exposure or, (b) be frustrated by intact nets before succeeding in blood-feeding on an unprotected individual the following night. Mosquito nets are an appropriate delivery system for pyriproxyfen, based on the large reductions in reproductive rate when blood-feeding between 1h and 24h after exposure. Combining with a pyrethroid should be an effective approach if susceptible mosquitoes are killed and resistant mosquitoes sterilized.
